---
title: "Edwards Lifesciences rises 1% on strong Q2 sales and raised guidance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293780839.md"
description: "Edwards Lifesciences (EW) climbs 1% during regular trading to $84.76 after beating Q2 estimates and raising full-year revenue guidance."
datetime: "2026-07-24T16:40:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293780839.md)
  - [en](https://longbridge.com/en/news/293780839.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293780839.md)
---

# Edwards Lifesciences rises 1% on strong Q2 sales and raised guidance

爱德华生命科学 (EW.US) 盘中时段涨**1.12%**，现报**84.76 美元**。该股触发盘中 5 分钟急涨信号，短期波动背景下日内涨幅相对温和。

消息面上，公司于 7 月 24 日公布第二季度业绩，每股收益**0.78 美元**、营收**17.4 亿美元**，双双超越分析师预估。公司上调全年营收指引至**66 亿至 69 亿美元**，主要受 TAVR（经导管主动脉瓣置换）和 TMTT（经导管二尖瓣和三尖瓣治疗）业务强劲销售驱动。

分析师维持看好立场，认为公司临床势头持续，但 Canaccord Genuity 重申**85 美元**目标价及 Hold 评级，指出 CMS 覆盖决定和 PROGRESS 试验结果等催化剂仍有待落地，且估值已反映增长预期。

### Related Stocks

- [EW.US](https://longbridge.com/en/quote/EW.US.md)

## Related News & Research

- [$100 Invested In Edwards Lifesciences 15 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/295852027.md)
- [Handelsbanken Fonder AB Has $139.42 Million Holdings in Edwards Lifesciences Corporation $EW](https://longbridge.com/en/news/295520666.md)
- [Edwards Lifesciences CVP TAVR Daniel J. Lippis melepas 619 saham senilai $ 56.966,57](https://longbridge.com/en/news/295581060.md)
- [Oklahoma Heart Institute joins national cardiovascular trials, uses Supira pVAD in SUPPORT II study](https://longbridge.com/en/news/295533024.md)
- [Kentucky Retirement Systems Lowers Stock Position in Edwards Lifesciences Corporation $EW](https://longbridge.com/en/news/294580308.md)